Family B of G-protein-coupled receptors (GPCRs) and their ligands play a central role in a number of homeostatic mechanisms in the endocrine, gastrointestinal, skeletal, immune, cardiovascular and central nervous systems. Alterations in family B GPCRregulated homeostatic mechanisms may cause a variety of potentially life-threatening conditions, signifying the necessity to develop novel ligands targeting these receptors. Obtaining structural and functional information on family B GPCRs will accelerate the development of novel drugs to target these receptors. Family B GPCRs are proteins that span the plasma membrane seven times, thus forming seven transmembrane domains (TM1-TM7) which are connected to each other by three extracellular (EL) and three intracellular (IL) loops. In addition, these receptors have a long extracellular N-domain and an intracellular C-tail. The upper parts of the TMs and ELs form the J-domain of receptors. The C-terminal region of peptides first binds to the Ndomain of receptors. This 'first-step' interaction orients the N-terminal region of peptides towards the J-domain of receptors, thus resulting in a 'second-step' of ligand-receptor interaction that activates the receptor. Activation-associated structural changes of receptors are transmitted through TMs to their intracellular regions and are responsible for their interaction with the G proteins and activation of the latter, thus resulting in a biological effect. This review summarizes the current information regarding the structure and function of family B GPCRs and their physiological and pathophysiological roles.
Introduction
Family B of G-protein-coupled receptors (GPCRs) consists of 15 members. It is also identified as a secretin-like family since the secretin receptor was the first to be cloned [1] . Family B GPCRs and the peptides that bind them are involved in a multitude of physiological and pathophysiological conditions. This renders family B receptors important targets for the development of peptide and non-peptide analogues.
Family B of GPCRs belongs to the superfamily of GPCRs, which also includes the families of rhodopsin, glutamate, adhesion and frizzled/taste2 and comprises the largest family of proteins in the human body [2] . GPCRs are proteins that span the plasma membrane seven times, thus forming seven transmembrane domains (TM1-TM7), which are connected to each other by three extracellular (EL) and three intracellular (IL) loops. The extracellular loops and the upper parts of the TMs form the J domain of receptors. In addition, these receptors have an extracellular N-domain (or ECD) and an intracellular C-tail. Binding of ligands to the extracellular region of family B GPCRs is associated with conformational changes. Such structural changes are transmitted through the transmembrane domains (TMs) to their cytoplasmic regions and are responsible for receptor interaction with G proteins and activation of the latter, thus resulting in biological responses.
The members of the family of B GPCRs are the following:
1. Calcitonin (CT) receptor (CTR) 2. Calcitonin receptor-like receptor (CRLR or CLR) 3. Corticotropin-releasing hormone (CRF) receptors type 1 (CRF1R) 4. CRF receptors type 2 (CRF2R) 5. Glucagon receptor (GCGR) 6. Gastric inhibitory polypeptide (GIP) receptor (GIPR) 7. Glucagon-like peptide 1 (GLP-1) receptor (GLP1R) 8. Glucagon-like peptide 2 (GLP-2) receptor (GLP2R) 9. Growth hormone-releasing hormone (GHRH) receptor (GHRHR) 10. Vasoactive intestinal peptide (VIP) receptors type 1 (VPAC1R) 11. VIP receptors type 2 (VPAC2R) 12. Pituitary adenylyl cyclase-activating protein (PACAP:
PACAP 27 , PACAP 38 ) receptor (PAC1R) 13. Parathyroid hormone (PTH) receptors type 1 (PTH1R) 14. PTH receptors type 2 (PTH2R) 15. Secretin receptor (SCTR) [2, 3] .
Each of these receptors is present in several different isoforms thus increasing the number of family B GPCRs to more than 15. For example, the CRF1R exists in isoforms identified as CRF-R1α, CRF-R1β, CRF-R1c, CRFR1d, CRF-R1e, CRF-R1f, CRF-R1g, CRF-R1h, whereas the isoforms of CRF2R are CRF-R2α, CRF-R2β and CRF-R2γ [4] .
CTR and CRLR can associate with the receptor activitymodifying proteins (RAMPs), RAMP1, RAMP2 and RAMP3 [5] [6] [7] [8] . RAMPs are plasma membrane proteins that have a single transmembrane domain, an extracellular N terminus and an intracellular C-region [9] . Association of CRLR with distinct RAMPs provides the receptor with different pharmacological properties. Association of CRLR with RAMP1 creates the receptor that binds CGRP, whereas its association with RAMP2 or RAMP3 creates the receptor that binds adrenomedullin. As CRLR, CTR is able to associate with RAMP1, RAMP2 and RAMP3 resulting in the formation of amylin receptors, AMY1, AMY2 and AMY3, respectively [10] . The CTR alone is a highaffinity receptor for calcitonin, whereas the AMY1 receptor has high affinity for amylin and CGRP. AMY2 and AMY3 receptors are high-affinity amylin receptors with lower affinity for related peptides [10] . Although the other family B GPCRs, such as CRF1R, VPAC1R, VPAC2R, GCGR, PTH2R and PTH1R, have been shown to associate with RAMPs, there is little information on the consequences of this complexation [11, 12] . In some cases, this interaction altered the signaling properties or cell surface expression of these receptors without however changing their binding phenotype [11, 12] .
Family B GPCRs and their ligands in homeostatic loops and their clinical significance
Family B GPCRs and their ligands play a central role in multiple homeostatic mechanisms within the endocrine, central nervous, immune, skeletal, cardiovascular and gastrointestinal systems (Fig. 1) . Alterations in family B GPCR-regulated homeostatic mechanisms are associated with a variety of potentially life-threatening pathophysiological conditions.
A variety of drugs targeting family B GPCRs have been created and are in clinical use to treat life-threatening diseases ( Table 1) . Modifications of GLP-1 led to the creation of marketed analogues, including liraglutide [13, 14] . Liraglutide treatment of patients with type 2 diabetes for 1 week improved their glycemic control [13] . Importantly, long-term administration of liraglutide to patients with type 2 diabetes improved glycemic control and showed extraglycemic effects, including beneficial effects on cardiovascular and renal outcomes [15] [16] [17] [18] . Similarly, amylin analogues, such as pramlintide, are used for the treatment of diabetes mellitus. Pramlintide has been shown to improve multiple glycemic parameters and reduce body weight (Table 1 ) [19] [20] [21] . Furthermore, the GHRH analog, tesamorelin, has recently been approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [22] . Antiretroviral therapy of HIV-infected patients could result in metabolic complications and changes in body composition. GHRH treatment of these patients is superior to GH treatment because GHRH stimulates the synthesis and pulsatile release of endogenous GH [22] . In contrast, exogenously administrated GH could lead to sustained levels of the hormone as it has several adverse effects including insulin resistance.
Teriparatide, a PTH analogue, is also therapeutically important since it is used for the treatment of osteoporosis (Table 1) [23] [24] [25] . Teriparatide not only increases bone mass but also improves microarchitecture, resulting in increased mechanical resistance and improved strength of bone. Recently, the PTH analogue abaloparatide received its first global approval, in the USA, for the treatment of postmenopausal women with osteoporosis at high risk of fracture [26, 27] . Other drugs targeting family B GPCRs which could also be used for the treatment of osteoporosis are calcitonin and its analogue elcatonin (Table 1) [28, 29] .
Marketed drugs that bind to family B GPCRs also include several GLP-2 analogues. Among them, teduglutide is used for the treatment of short-bowel syndrome and other gastrointestinal disorders [30] [31] [32] . Moreover, there are many ligands for family B GPCRs that are in clinical trials, such as the human monoclonal antibody Erenumab, which inhibits the CGRPR, for the prevention of migraine [33, 34] , and drugs targeting the CRF receptors. Small non-peptide CRF1R-selective antagonists are in clinical trials for the potential treatment of anxiety and irritable bowel syndrome [35, 36] , while a synthetic preparation of CRF (corticorelin) is being considered as a potential treatment for the reduction of peritumoral cerebral oedema, as a result of the leakage of oedematous brain tumour fluid from abnormal tumour vasculature (Table 1) 
Interaction of family B GPCRs with their ligands
Structural-functional properties of peptides of family B GPCRs
The peptides of family B GPCRs contain a central region which connects an amino-terminal (N-terminal region) with a carboxyl-terminal region (C-terminal region). Alanine mutations of several N-and C-terminal residues of CRF, VIP and PACAP decreased or led to complete loss of their binding and/or biological activity [39] [40] [41] [42] [43] [44] [45] . These studies suggest the functional importance of N-and C-regions of peptides for family B GPCRs. Additional studies have suggested that the C-terminal region of peptides is mostly important for ligand binding, whereas their N-terminal region is essential for receptor activation. Differential truncation of the C-terminal region of PACAP resulted in a decrease or loss of binding of peptide to its receptors [46] . As PACAP, deletion of amino acids from the C-terminal region of CRF decreased its biological activity, possibly as a result of decreased ability of the peptide to bind to its receptor [47] . Likewise, deletion of Cterminal residues from the CRF analogue, urotensin, resulted in truncated peptides that decreased biological activity of urotensin without, however, abolishing it [48] . In contrast, deletion of N-terminal residues from urotensin resulted in biologically inactive analogues [48] . Similarly, deletion of the first eight N-terminal residues of CRF resulted in loss of its biological activity [49] . Interestingly, this inactive truncated analogue still bound to its receptor antagonizing the biological actions of CRF [49] . Likewise, several N-terminally truncated analogues of VIP, exendin (a GLP-1-related peptide) and calcitonin analogues, did not display agonist properties [50] [51] [52] [53] . However, they were able to bind to their receptors, displaying antagonistic properties. The ability of peptides to bind to receptor and simultaneously lose their biological activity, after truncation of their N-terminal region, was used to create potent antagonists.
In addition to their C-and N-termini, an important role in the biological activity of peptides is played by their ability to adopt an α-helical conformation [54] [55] [56] [57] [58] [59] [60] . It is possible that peptides, before reaching their receptors, could pre-form a helical structure within the plasma membrane. A two-step ligand transportation model has been proposed in a previous study in which a peptide initially binds nonspecifically to plasma membrane to form an α-helix in its C-terminal region, and then diffuses in search of its receptor [60] . This model is in agreement with the abilities of peptides to adopt an α-helical conformation in hydrophobic or amphiphilic environments [55, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] . In contrast, in aqueous solutions, these peptides are generally disordered.
Replacement of CRF residues by α-helical preferring ones maximized the α-helix-forming potential of peptide and resulted in an increase of its biological potency [49] . Moreover, connecting the N-and C-terminal regions of CRF and the CRF-related peptide, urocortin, with a linker rich in alanines (Ala has high helix forming propensity [73] ) or with highly charged linkers forming α-helices resulted in analogues equipotent to parental peptides [74] . In contrast, connecting the N-and C-terminal regions of CRF peptides with highly flexible linkers created analogues with decreased biological potencies [74] . It has also been proposed that reducing the probability of calcitonin peptides to form an amphipathic helix structure decreases binding to their receptors [75] . Differences in the helicity of GLP-1 and exendin could also contribute to their different binding affinities for the N-domain of GLP1R [76] .
Two-domain binding model of ligand/receptor interaction
The two-domain binding model suggests that the C-and Nterminal regions of peptides interact with the N-and Jdomains of receptors of family B GPCRs, respectively. The interaction C-region of the peptide/N-domain of the receptor has been suggested in previous crystallization and NMR studies of N-domains of different receptors in complex with their ligands [54-59, 77, 78] . This mode of interaction has also been suggested in several mutagenesis studies as well as in a biophysical study which has shown that the C-terminal region of secretin binds to a groove above a beta-hairpin region of the N-domain of its receptor [79] . In mutagenesis studies, N-terminally truncated analogues of CRF, urocortin and exendin (with intact C-terminal regions) have been shown to bind with high affinity either to fragments of their receptors containing the N-terminal domain or to receptors maintaining their N-domain and lacking the J-domain, which has been replaced by the corresponding region of a different receptor [76, [80] [81] [82] . The interaction between the C-terminal region of peptides and the N-domain of receptors has also been suggested as being important for the binding of adrenomedullin, glucagon and GLP-1 to their receptors [45, 83] . Supportive evidence for this mode of peptide/receptor interaction has been provided in a photocrosslinking study of CTR, which showed that the C-terminal amino acid 26 of calcitonin is in close proximity to Thr30 of the N-domain of the receptor [84] .
The interaction N-region of the peptide/J-domain of the receptor has been suggested in a mutagenesis study of CRF1R [85] . Specifically, Trp259 and Phe260 in the second extracellular loop (EL2) of the J-domain of CRF1R have been shown to interact with N-terminal residues 8-10 of sauvagine and the corresponding region of CRF. In accordance with these findings, a previous photocrosslinking study has demonstrated that Lys257 of the EL2 of CRF1R lies near the N-terminal region of CRF peptides [86] . In addition to EL2, EL1, TM1, TM5, TM6 and TM7 of the J-domain of CRF1R have been shown to be in close proximity to the N-terminal region of CRF peptides [87] [88] [89] . Similarly, the amino acids in the N-terminal region of PTH, secretin, calcitonin, glucagon and GLP-1, have been demonstrated to be in close proximity to the J-domain of their receptors in previous studies using a variety of different methodologies [83, [90] [91] [92] [93] [94] [95] [96] . The interaction between the N-terminal region of peptides and the Jdomain of receptors is crucial for receptor activation. This observation is supported by the aforementioned functional importance of the N-region of peptides and by the results of a mutagenesis study which used chimeras consisting of the Jdomain of the calcitonin receptor (J-CTR) and the N-domain of the PTH receptor (N-PTHR) and vice versa, as well as hybrid peptides consisting of the C-region of PTH (PTH-C) and the N-region of calcitonin (CT-N) and vice versa [97] . A chimeric receptor (for example, N-PTHR + J-CTR) was activated only by the hybrid peptide, which is composed of a Nterminal region (for example, CT-N) that corresponds to the Jdomain of the receptor (J-CTR) and a C-terminal region (for example, PTH-C) that matches the N-domain of the receptor (N-PTHR).
Two-step binding model of ligand/receptor interaction
The interaction of peptides, such as PTH or CRF, with their family B GPCRs has been proposed as involving two steps (Fig. 2 ) [98] [99] [100] . In the first step, the C-terminal region of peptides interacts with the N-domain of receptors. It has been suggested that this "first-step" interaction orients the Nterminal region of peptides towards the J-domain of the receptor, resulting in their interaction with each other. This "secondstep" interaction is responsible for receptor activation.
Peptides lacking the N-terminal region are antagonists because they bind to the N-domain of the receptor in the "firststep" interaction, thus blocking agonist binding, but cannot proceed to the "second-step" as they cannot bind to the Jdomain and activate the receptor. The two-step model of ligand/receptor interaction is further supported by a study that replaced the N-domain of CRF1R by the first 16 N-terminal residues (signaling region of CRF [101] ). This created the chimeric receptor, CRF [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] /R1ΔN, in which the Nterminal region of CRF was tethered to the J-domain of the receptor. Such tethering mimicked the "first-step" of receptorpeptide interaction that placed the signaling region of CRF close to the J-domain of CRF1R to interact with each other According to the two-step model, the C-terminal region of peptides (red) interacts with the N-domain of receptors. This "first-step" interaction orients the N-terminal region of peptides (blue) towards the J-domain of the receptor, resulting in their interaction with each other. This "second-step" interaction is responsible for receptor activation and activate the receptor. Indeed, the CRF [1-16]/R1ΔN chimera was active in the absence of an exogenously administrated agonist (constitutively active receptor). Antalarmin binds to the TMs of the CRF [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] /R1ΔN chimera and blocks receptor activation [102] . In contrast, the constitutive activity of the CRF [1-16]/R1ΔN chimera was not blocked by astressin, which interacts with the N-domain of wild-type CRF1R [101] .
The two-step model of ligand binding and receptor activation is supported by a FRET study which tagged the PTH with tetramethyl-rhodamine and its receptor with green fluorescent protein (GFP) [103] . The results of this study suggested that PTH initially interacts with the N-domain of its receptor ("first-step" interaction) with a fast time constant (τ =1 40 ms) and then ("second-step" interaction) with the Jdomain of the receptor more slowly (τ =~1 s). These data also suggested that the slow "second-step" interaction coincides with an activation-associated conformational change of receptor.
Structural and functional characteristics of the N-domain and TMs of family B GPCRs
The N-domain Based on the data of NMR and crystallography studies, the Ndomain of family B GPCRs has a conserved structural motif (α-β-β-α motif), which consists of the following: (1) a Nterminal α-helix, (2) two anti-parallel β-sheets, termed β1-β2 and β3-β4, each consisting of two β-strands (Figs. 3 and 4) and (3) an α-helical C-terminal region [54-59, 77, 78, 104-109] . β-sheet topology is known as the short consensus repeat (SCR) or Sushi domain. Sushi domains play an important role in protein-protein interactions, such as those of the complement system [77, 105, 110, 111] . Loop 2 (β1-β2 loop) connects the β1 and β2 strands of the β1-β2 sheet, whereas loop 4 links the β3 and β4 strands of the β3-β4 sheet. The Nterminal α-helix and β1-β2 sheet are connected with each other by loop 1. Three highly conserved disulfide bonds (S-S bonds) link these sheets with each other and with other regions of the N-domain, thus stabilizing the β-sheets [54-59, 77, 78, 104-106, 109] . The first S-S bond links the β1-β2 sheet and the N-terminal α-helix, the second connects the two β-sheets with each other and the third links the β3-β4 sheet with the C-terminal domain [58] . Stabilization of Ndomain structure by the three disulfide bonds is crucial for receptor function, since disruption of these bonds in GLP1R, VIPR and CRF1R using β-mercaptoethanol, DTT or mutating the Cys had dramatic effects on ligand binding and biological potency [112] [113] [114] .
In addition to the three conserved disulfide bonds, the structure of the N-domain of family B GPCRs is stabilized by hydrophobic, electrostatic and hydrogen-bond interactions mostly between six conserved residues of this domain (Fig. 3 ) [54-59, 77, 78, 104-109] . These six conserved residues were Asp (termed Asp1; Asp49 and Asp65 of CRF1R and CRF-R2β, respectively), Trp (termed Trp2; Trp55 and Trp71 of CRF1R and CRFR-2β, respectively), Pro (termed Pro3; Pro69 and Pro85 of CRF1R and CRFR-2β, respectively), Arg (termed Arg4; Arg85 and Arg101 of CRF1R and CRFR-2β, respectively), Gly (termed Gly5; Gly91 and Gly107 of CRF1R and CRFR-2β, respectively) and Trp (termed Trp6; Trp93 and Trp109 of CRF1R and CRFR-2β, respectively). All these residues, except Arg, are identical in family B GPCRs; Arg is Lys in CRLR, CTR, GCGR and VPAC2R. Although Arg is not identical in all members of family B GPCRs, a positively charged residue (either Arg or Lys) at this position is completely conserved among all receptors, suggesting its important functional role.
The interactions between the conserved residues of the Ndomain are crucial for the stabilization of its functional structure. It has been proposed that the interaction between Asp1 and Trp2 stabilizes the loop 2, thus contributing to the formation of the correct geometry of ligand contact sites [77, 108] . In addition, mutations of Asp1 and Arg4 most likely disrupt the structure of the N-domain of the PAC1 receptor, resulting in a misfolded or less stable structure with altered ligandbinding properties [57] . Similarly, mutation of these residues to Ala disrupted a salt bridge between them and resulted in the collapse of a well-defined three-dimensional structure of the N-domain of the CRF receptor into a molten globule-like conformation [108] . Interestingly, mutation of Asp1 in the GHRH receptor impaired its function, resulting in a genetically transmitted dwarfism in mice [115] . This genetic abnormality is referred to as little (lit/lit) and is characterized by hypoplasia of the anterior pituitary and decrease of growth hormone mRNA and protein [115] .
Peptide binding to the N-domain of family B GPCRs is associated with adoption of an α-helical conformation of peptides [54] [55] [56] [57] [58] [59] 77] . This α-helical conformation allows hydrophobic interactions of peptides with the receptor via one face of their α-helix and hydrophilic interactions via the other face [54, 55] . Despite this conserved mode of binding, various ligands of family B GPCRs bind differentially to their receptors. PACAP interacts with PAC1R on one face of the Ndomain, whereas other peptides, such as PTH, GIP, GLP-1, CRF and astressin, bind on the opposite face (Fig. 4) [54, 56-59, 77, 105, 109] . Moreover, different peptides, such as PTH, GIP, GLP-1, CRF and astressin, which interact with the same face of the N-domain of their receptors, are positioned slightly differently. For example, PTH and GIP are shifted approximately 5-8 Å as compared with CRF [77] . This might be partly due to the presence of Gly52 in loop 2 of the Ndomain of CRF1R, which is not present in the other family B GPCRs [77] . Gly52 causes loop 2 to adopt a conformation that is not stereochemically compatible with PTH or GIP located at the same position as CRF.
The role of the N-domain in ligand selectivity has also been proposed by Pal et al. who compared the electrostatic surface potentials of the crystal structures of the N-domain of CRF1R and CRF2R [78] . This study suggested that the positively charged Arg35 of the non-selective CRF is electrostatically compatible with Glu104 of CRF1R as well as with the hydrophobic surface created by Pro100 of CRF2R, which corresponds to Glu104 of CRF1R [78] . In contrast, the hydrophobic Ala35 (that corresponds to Arg35 of CRF) of the CRF2R-selective CRF analogues, urocortins II and III, is compatible with Pro100 of CRF2R but not with Glu104 of CRF1R.
An additional determinant of ligand selectivity is the association of family B GPCRs with RAMPs, which are proteins Fig. 4 Hormone binding to the respective N-domains of their receptor. N-domains and peptides are shown in cartoon representation. The β-strands of the β-sheets of the N-domains are depicted as purple arrows, whereas the N-terminal α-helix is cyan colored. In specific, a Ucn 1 bound to CRF2R in orange, b PACAP bound to PACAPR in gray, c parathyroid hormonerelated protein (PTHrP) bound to PTH 1 R in green, d GLP-1 bound to GLP1R in yellow, e GIP bound to GIPR in red and f CRF bound to CRF1R in blue. PACAP interacts with receptor on one face of the N-domain, whereas other peptides bind on the opposite face spanning once the plasma membrane and having an extracellular N-terminus and a cytoplasmic C-terminus [116] . RAMPs play an important role in ligand selectivity, receptor trafficking and differential coupling of CPCRs with various G proteins [117, 118] . Molecular determinants that account for distinct pharmacological profiles of a receptor complexed with different RAMPs are discussed in detail in the reviews of Archbold et al. and Hay et al. [117, 119] The transmembrane domains
The structural changes that take place in the N-domain and the extracellular loops of family B GPCRs upon ligand binding are transmitted through the transmembrane domains (TMs) to their intracellular loops and C-tail and are responsible for receptor interaction with G proteins and activation of the latter [120] .
Beginning in 2013, the structure of the helical TMs of two family B GPCRs was solved in three crystallographic studies on the inactive GCGR [121] , the GCGR in complex with the extrahelical allosteric antagonist MK-0893 [122] and the CRF1R bound to the allosteric antagonist CP-376395 [123] . More recently, the crystal and cryo-EM structures of the GLP1R and the full-length GCGR, bound to negative allosteric modulators, as well as CTR and GLP1R in their active states bound to peptide agonists and the heterotrimeric G s protein have been reported (Fig. 5a, b) [124] [125] [126] [127] . The structure of GLP-1R bound to the GLP1 peptide agonists and the G s protein using cryo-EM visualization revealed specific features on the mechanism of transmembrane reorientation during activation of family B GPCRs (Fig. 5a) . The other structure of a family B GPCR in complex with a G protein was CTR, however without the presence of the ECD (Fig. 5b) . This structure also revealed the binding mode of the peptide agonist as well as intracellular motions that govern GPCR activation. These receptors share the same seven transmembrane architectures as GPCRs of other families despite the fact that the most conserved residues of each TM are different, except TM4 in which Trp 4.50 is conserved among families A, B and F [128] . Trp 4.50 is numbered according to the Ballesteros-Weinstein numbering scheme which has been used to number conserved TM residues in family A GPCRs [129] . Based on the Ballesteros-Weinstein numbering scheme, the fully conserved TM residues in family A receptors are named X.50 (where X is the number of the TM and 50 is the most conserved residue), whereas the neighbouring residues immediately before and after X.50 are named X.49 and X.51, respectively. For family B GPCRs, the conserved residues were numbered according to the Wootten numbering [130] . Although the receptors of families A and B are different, their overall fold is similar allowing the alignment of the sequences of receptors in both families based on their structures [102, 121] . This alignment enabled us to use the Ballesteros-Weinstein general scheme to number TM residues of receptors of both families in this manuscript. This makes feasible the comparison of receptor structures belonging to family A and B GPCRs.
Comparison of the structures of family A and B GPCRs reveals that there are structural similarities and differences between their TMs. A common characteristic is the highly conserved GWGxP motif in TM4 that forms a network of structurally important interactions with TM2 and TM3 [123] . In addition, it has been proposed that a TM1-TM7 interaction between Ser 1.46 , Ser 7.43 and Phe357 7.47 stabilizes a kink in TM7 [123] . This TM7 kink is different than the corresponding one in family A GPCRs and is responsible for the larger binding pocket (formed by the extracellular portions of TMs) of family B GPCRs compared to that of family A receptors. This large V-shaped ligand-binding pocket of family B receptors enables the helical hormones to reach this cavity and bind to it to promote activation.
Activation-associated conformational changes of family B GPCRs are much less elucidated than family A receptors. However, the few recently identified structures of family B GPCRs show a similar activation mechanism, where the important element is the outward movement of the TM6 intracellular part [124] [125] [126] [127] . The crystal structure of family A, β 2 adrenergic receptor in complex with the G s protein, has revealed a 14 Å outward movement of the intracellular part of TM6 of receptor [131] . During the activation of family B GPCRs, structural changes in the intracellular parts of TMs as well as the intracellular regions (IL1-IL3) are responsible for receptor interaction with, and activation of, multiple G proteins, such as G s , G q/11 and G i/o [132] [133] [134] .
Among the intracellular regions of family B GPCRs, IL3 and the intracellular parts of TM5 and TM6 have been shown to mostly participate in receptor/G protein interaction, similarly to family A GPCRs. Simultaneous disruption of the cationic amino acids of IL3 near TM5 and TM6 by tandem Ala mutations abolished the ability of CRF1R to activate G proteins [135] . Importantly, different amino acids in these regions confer the selectivity of IL3 interaction with different G proteins. Arg292, Arg310 and Lys311 have been shown to be important in the interaction of IL3 with both G s and G i proteins, whereas Leu294, Met295 and Lys314 exhibited G s protein interaction selectivity. The participation of hydrophobic residues of IL3 in receptor/G protein interaction, in addition to ionic residues, has also been shown in different other receptors. It has been suggested that Ile290 at the proximal end of IL3 of CGRP1R interacts with G s as well as with TM6 to stabilize the conformation of IL3 [136] . Moreover, Ala mutation of Val378 and Leu379 in IL3 of PTHR reduced receptor signaling [137] . As in CRF1R, different amino acids in the IL3 of the PTHR play a differential role in receptor interaction with different G proteins and activation of different signaling pathways [137] . Ala mutation of Val378 and Leu379 in IL3 of PTHR reduced inositol phosphate (IP) production, without affecting cAMP responses to PTH. In contrast, Ala mutation of the neighbouring Thr381 decreased cAMP accumulation without altering IP responses to PTH. Similarly, different domains in the IL3 of the GLP1R are responsible for G s and G i activation [138] . The N-terminal part of IL3 of GLP1R selectively stimulates G s , whereas the C-terminal part stimulates G i proteins. In addition to GLP1R, the crucial role of IL3 in family B GPCRs/G protein interaction has also been demonstrated in many studies on different receptors, such as VPAC1R, GCGR and secretin receptor [136, [139] [140] [141] [142] [143] [144] [145] .
Using peptides derived from IL1, IL2 and IL3 of GLP1R, Bavec et al. have shown that in addition to IL3, which stimulated all G proteins (G s , G o , G i and G 11 ), IL1 and IL2 participated in receptor/G protein interaction by modulating the interactions between IL3 and different G proteins [143] . IL1 and IL2 of many family B GPCRs have also been shown to interact with G proteins [136, 140, 144, 146] .
The ability of family B GPCRs to interact with different G proteins and the differential contribution of different amino acids of receptor intracellular regions in these interactions are likely related to their property to adopt various conformations. Interestingly, different conformations of a receptor could also be responsible for its differential signaling through the same G protein. PTH and PTHrP have been suggested as preferentially stabilizing distinct active conformations of PTHR that can be distinguished kinetically at several steps of binding and activation [147] . PTH induces a 'locked on' active PTHR conformation, which is correlated with the formation of Rab5-positive endosomal compartments containing ligand, receptor, G s and adenylyl cyclase. Thus, PTH mediates persistent G s protein activation by moving to internalized compartments where it remains associated with PTHR and G s . In marked contrast, PTHrP action is restricted to the cell surface where it dissociates rapidly from PTHR, prompting rapid signal termination. The ability of PTH to induce a more stable active complex with PTHR than PTHrP is physiologically important as it could be related to the higher propensity of PTH to activate bone-resorption (less bone-anabolic) than PTHrP [147] . Thus, the different duration of PTHR signaling after its activation by different ligands could determine the net physiological effect on the opposing processes of bone formation and bone resorption.
It is suggested that the association of family B GPCRs with RAMPs may alter their interaction with different G proteins [117, 118] . To determine the effects of the association of CLR with different RAMPs on receptor signaling through G i and G s proteins, Weston et al. measured G s -mediated cAMP production in HEK 293 cells before and after pertussis toxin (PTX) treatment [118] . PTX uncouples receptors from G i proteins and therefore removes any inhibition of cAMP production. PTX pretreatment of cells co-expressing RAMP1 and CLR resulted in little increase in CGRP-mediated cAMP production. In contrast, PTX pretreatment largely increased adrenomedullin or adrenomedullin2-mediated cAMP production, suggesting strong G i signaling for both of these ligands that had been removed by PTX treatment. Association of CLR with RAMP2 or RAMP3 created a different signaling phenotype of CLR since PTX increased CGRP and adrenomedullin2-mediated cAMP production but not that of adrenomedullin. Interestingly, the effects of RAMPs on CLR signaling were different in various cells displaying different levels of expression of G proteins [118] .
Structural determinants of allosteric binding of non-peptide molecules and antagonism
Small non-peptide antagonists have been shown to intercalate between TMs and interact with them to allosterically block peptide binding and receptor activation-associated conformational changes [102, 123] . The crystal structures of GCGR 122 and CRF1R [123] in complex with an allosteric antagonist highlighted unexpected binding positions in both receptors, compared to GPCRs belonging to different families. GPCR structures from families A, C and F have shown ligands to cluster in pockets close to the extracellular part of receptors [128] . In comparison to family A GPCRs, family B receptor structures suggest that non-peptide ligands might bind deeper towards the intracellular portions of TMs (Fig. 5c, d) . The GCGR-MK-0893 structure revealed that the ligand binds towards the intracellular part and outside the 7TM and interacts with residues of TM5, TM6 and TM7 (Fig. 5c) [122] . Likewise, negative allosteric modulators PF-06372222 and NNC0640 bind in the same region of GLP1R [124] . This "clamp-like" binding mode is thought to restrict TM6 in its position, prohibiting the outward movement needed for activation [131, 148] and Asn404 7.57 . Similarly, allosteric antagonists PF-06372222 and NNC0640 co-crystallized with GLP1R, bind to the same location. These structures could be used as guides for the design of such "extrahelical" antagonists that directly block the helical movements associated with GPCR activation.
The CRF1R crystal structure has shown a non-expected binding site of the allosteric antagonist, CP-376395, located only ∼ 4 Å from the intracellular boundary of receptor between TMs 3, 5 and 6 (Fig. 5d) . 123 In this hydrophobic pocket, CP-376395 interacts hydrophobically with Phe284 form a lid-like structure that restricts it within the binding pocket. As CP-376395, Phe203 has been found to contact another CRF1R-selective ligand, antalarmin [102] . Although amino acids that form the allosteric binding pocket are conserved between the two CRF receptors, they, however, cannot be considered as a common binding site for small molecules in these receptors. CP-376395 is highly selective towards CRF1R, having an affinity for CRF1R 10,000-fold higher than that for CRF2R [149] . This is the case of most of the CRF1R allosteric non-peptide antagonists, which share the same main pharmacophoric characteristics [35] . The selectivity of these compounds could be attributed to a possible important indirect role of residues His199 3.36 and Met276 5.47 of CRF1R in non-peptide ligand binding [123, 150] . These residues do not interact with CP-376395 as demonstrated in the crystal structure of CRF1R [123] . However, mutation of these residues in CRF1R to their corresponding CRF2R amino acids Val199 ; thus, this observation supports the important role of these residues in non-peptide ligand CRF1R selectivity. The latter assumption is supported by a recent study which, using molecular dynamics simulations, pointed to the importance of Tyr327 6.53b , linking it to His199 3.40b [152] . The accumulating structural information on allosteric binding of family B GPCRs could identify druggable regions, such as the outside of the transmembrane domains of GCGRs. This would enable the development of non-conventional computational methods towards virtual screening and drug design on sites that interact with the membrane environment.
Conclusions
Maintenance of homeostasis is a basic prerequisite for life, ensuring the stability of the human body in response to external and internal stimuli (stressful stimuli). The maintenance of homeostasis requires numerous adaptive responses, involving, inter alia, alterations in the function of the endocrine system. A central role in the maintenance of homeostasis is played by family B GPCRs and their ligands by regulating the activity of the endocrine system as well as that of the gastrointestinal, skeletal, immune, cardiovascular and central nervous systems. Given that alterations in family B GPCRregulated homeostatic mechanisms affect human physiologic functions and are associated with a variety of pathophysiological conditions, the development of novel ligands targeting this family of receptors will enhance our efforts to combat various potential life-threatening diseases. While already several drugs targeting family B GPCRs are now clinically being used to treat diabetes mellitus, osteoporosis and other serious diseases, many other ligands are currently in clinical trials. Obtaining information about the structure of family B GPCRs, such as the recent cryo-EM structures, which is reviewed in this manuscript, are providing mechanistic insights not only into their activation but also regarding their targeting by small molecules. This information will further advance the development of novel drugs targeting family B GPCRs which will enrich the therapeutic armory for the treatment of a wide range of serious disorders.
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